Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $13,132.35 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 4,169 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $3.15, for a total transaction of $13,132.35. Following the completion of the transaction, the insider now directly owns 134,921 shares of the company’s stock, valued at approximately $425,001.15. The trade was a 3.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Gina Mazzariello also recently made the following trade(s):

• On Monday, February 3rd, Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock. The shares were sold at an average price of $3.49, for a total value of $12,836.22.

Amylyx Pharmaceuticals Stock Up 3.8 %

NASDAQ:AMLX opened at $3.28 on Friday. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $19.42. The firm has a market capitalization of $224.84 million, a price-to-earnings ratio of -0.86 and a beta of -0.54. The stock’s 50 day moving average price is $3.60 and its two-hundred day moving average price is $3.82.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Finally, Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $3.00 to $11.00 in a report on Monday, November 18th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Blue Trust Inc. lifted its stake in Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after acquiring an additional 4,883 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Amylyx Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after purchasing an additional 5,104 shares during the period. XTX Topco Ltd raised its holdings in shares of Amylyx Pharmaceuticals by 12.0% in the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock valued at $202,000 after purchasing an additional 5,704 shares during the period. Northern Trust Corp lifted its stake in Amylyx Pharmaceuticals by 11.8% in the 4th quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after purchasing an additional 11,214 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth about $45,000. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.